Tag - ZIOP

Developments

Ziopharm doses first patient in Phase 1/2 pediatric brain tumor trial

Ziopharm Oncology (NASDAQ:ZIOP) dosed the first patient in its Phase 1/2 trial evaluating controlled IL-12 for the treatment of diffuse intrinsic pontine glioma (DIPG). Ziopharm’s controlled IL-12 is a gene therapy...

July 8, 2020

Developments

Ziopharm completes enrollment of Phase 2 glioblastoma trial

Ziopharm Oncology (NASDAQ:ZIOP) completed enrollment of 36 subjects in its Phase 2 trial evaluating controlled IL-12, in combination with PD-1 inhibitor cemiplimab, for the treatment of recurrent or progressive...

June 22, 2020

Developments

FDA clears Ziopharm Oncology IND for CAR-T therapy

The FDA has cleared Ziopharm Oncology’s (NASDAQ:ZIOP) IND for CD19-specific CAR-T for the treatment of relapsed CD19+ leukemias and lymphomas. The drug candidate is based on Ziopharm’s non-viral T cell modification...

October 1, 2019

Developments

FDA clears Ziopharm Oncology IND for T-cell receptor therapy

The FDA has cleared Ziopharm Oncology’s (NASDAQ:ZIOP) IND for its T-cell receptor therapy (TCR-T) for the treatment of solid tumors. Ziopharm’s TCR-T consists of T-cells that have been genetically modified to express...

June 11, 2019

Developments

Ziopharm glioblastoma program gets FDA fast track designation

Ziopharm Oncology’s (NASDAQ:ZIOP) controlled IL-12 program received FDA fast track designation for the treatment of recurrent or progressive glioblastoma multiforme (rGBM) in adults. Controlled IL-12 consists of IL-12...

April 3, 2019

Tag - ZIOP

Ziopharm doses first patient in Phase 1/2 pediatric brain tumor trial

Ziopharm completes enrollment of Phase 2 glioblastoma trial

FDA clears Ziopharm Oncology IND for CAR-T therapy

FDA clears Ziopharm Oncology IND for T-cell receptor therapy

Ziopharm glioblastoma program gets FDA fast track designation

General

More